Zur Rose Group accelerates internationalisation Dienstag, 12. März 2019 - 07:01

Zur Rose Group AG / Key word(s): Expansion
Zur Rose Group accelerates internationalisation

12.03.2019 / 07:00

---------------------------------------------------------------------------

Press release

Zur Rose Group accelerates internationalisation

The Zur Rose Group is pressing ahead with its internationalisation and
extending its marketplace business model to France. In this context, the
Group has acquired the French marketplace Doctipharma from the Lagardère
group, Paris, thus already securing a strong competitive position when it
enters the market.

The Doctipharma platform has over 100 partner pharmacies selling more than
15,000 health, beauty and personal care (BPC) products. Doctipharma is
linked to France's largest health information website, Doctissimo, which
generates additional traffic. In the coming months, Doctipharma will be
integrated into the marketplace platform developed by PromoFarma, creating
synergies, providing customers with access to the unique transnational
product catalogue and giving pharmacies access to new online shoppers.

In Spain, the Zur Rose subsidiary PromoFarma sells more than 70,000 standard
BPC products from around 5,000 different brands on its platform, which are
provided and shipped by nearly 700 partners, pharmacies and pharmaceutical
manufacturers. PromoFarma is the leading platform in the BPC segment in
Southern Europe.

Investors and analyst contact
Marcel Ziwica, Chief Financial Officer
Email: ir@zurrose.com, phone: +41 58 810 11 49

Media contact
Lisa Lüthi, Head of Corporate Communications
Email: media@zurrose.com, phone: +41 52 724 08 14

Financial Calendar
21 March 2019 Annual Results 2018
17 April 2019 Q1/2019 Trading Update
23 May 2019 Annual General Meeting
21 August 2019 2019 Half-Year Results
23 October 2019 Q3/2019 Trading Update

Zur Rose Group

The Swiss Zur Rose Group is Europe's largest e-commerce pharmacy and one of
the leading medical wholesalers in Switzerland. With its business model, it
offers high-quality, safe and cost-effective pharmaceutical care and thus
contributes to reducing healthcare costs. It is also characterized by the
continuous further development of digital services in the field of drug
management and actively promotes its positioning as a comprehensive,
integrated cross-service healthcare platform. The creation of added value
and a pronounced patient orientation make the Group an important strategic
partner for service providers, cost units and industry.

The Zur Rose Group is internationally present with strong brands, including
Germany's best-known pharmacy brand DocMorris. The company employs over
1,300 people at various locations and generated a turnover of CHF 1,207
million in the 2018 financial year. The shares of Zur Rose Group AG are
listed on the SIX Swiss Exchange (securities number 4261528, ISIN
CH0042615283, ticker ROSE). The CHF 115 million corporate bond issued in
July 2018 is also listed on the SIX Swiss Exchange (securities number
42146044, ISIN CH0421460442, ticker ZRO18). Further information at
zurrosegroup.com